Estrogen-androgen for hormone replacement: A review

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 42, Issue 7, 1997, Pages 394-404

  Rosenberg, Michael J ^a,b   King, Timothy D N ^a   Timmons, M Chrystie ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Health Decisions Inc   (United States)

Author keywords

Androgens; estrogens; Hormone replacement therapy; Post menopausal

Indexed keywords

ANDROGEN; CONJUGATED ESTROGEN; ESTRATEST; ESTROGEN; ESTRONE; FLUOXYMESTERONE; METHYLTESTOSTERONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; ARTICLE; DRUG EFFICACY; DRUG RESEARCH; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HUMAN; LIBIDO; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; WELLBEING;

AFFECTIVE SYMPTOMS; ANDROGENS; BONE DENSITY; CHOLESTEROL, HDL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIBIDO; POSTMENOPAUSE; TRIGLYCERIDES;

EID: 0030790481     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Hammond CB: Women's concerns with hormone replacement therapy: Compliance issues. Fertil Steril 1994;62: 157S-160S
2. de Lignières B, Weill E, Mauvais-Jarvis P, et al: Relations interactives entre comportements sexuels et hormonothérapie substitutive post-ménopausique: Enquête SOFRES. Rev Fr Gynecol Obstet 1990;85:581-586
3. Alden JC: Osteoporosis: A review. Clin Ther 1989;11:3-14
4. Sherwin BB, Gelfand MM, Brender W: Androgen enhances sexual motivation in females: A prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985;47:339-351
5. Frisch RE, Canick JA, Tulchinsky D: Human fatty marrow aromatizes androgen to estrogen. J Clin Endocrinol Metab 1980;51:394-396
6. Vermeulen A: Sex hormone status of the postmenopausal women. Maturitas 1980;2:81-89
7. Rossmanith WG, Scherbaum WA, Lauritzer C: Gonadotropin secretion during aging in postmenopausal women. Neuroendocrinology 1991;54:211-218
8. Carr BR, Wilson JD: Disorders of the ovary and female reproductive tract. In Harrison's Principles of Internal Medicine. Thirteenth edition. Edited by K Isselbacher, E Braunwald, JD Wilson. New York, McGraw-Hill, 1994, pp 2017-2036
9. Weiss R: Prescription for passion: Menopausal women using testosterone. Good Housekeeping 1995;9:100
10. Jancin B: Postmenopausal testosterone therapy questioned. Ob-Gyn News, Jan 15, 1996
11. Gambrell RD Jr: Prevention of endometrial cancer with progestogens. Maturitas 1986;8:159-168
12. Lindsay R: The burden of osteoporosis: Cost. Am J Med 1995; 98:9S-11S
13. Baran DT, Bergfeld MA, Teitelbaum SL, et al: Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male. Calcif Tiss Res 1978;26:103-106
14. Raisz LG, Wiita B, Artis A, et al: Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996;81:37-43
15. Wilson JD: Androgens. In Goodman and Gilman's Pharmacological Basis of Therapeutics. Ninth edition. Edited by JG Hardman, LE Limbard, PB Molinoff, et al. New York, Pergamon Press, 1996, pp 1441-1457
16. Eriksen EF, Colvard DS, Berg NJ, et al: Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241:84-86
17. Nordin BEC, Robertson A, Seamark RF, et al: The relation between calcium absorption, serum dihydroepiandrosterone and vertebral mineral density in postmenopausal women. J Clin Edocrinol Metab 1985;60:651-657
18. Henneman PH, Wallach S: The use of androgens and estrogens and their metabolic effects: A review of the prolonged use of estrogens and androgens in postmenopausal and senile osteoporosis. Arch Intern Med 1957;100:715-723
19. Need AG, Chatterton BE, Walker CJ, et al: Comparison of calcium, calcitrol, ovarian hormones and nandrolone in the treatment of osteoporosis. Maturitas 1986;8:275-280
20. Need AG, Horowitz M, Morris HA, et al: Effects of nandrolone therapy on forearm mineral content in osteoporosis. Clin Orthop 1987;225:273-278
21. Davidson BJ, Ross RK, Paganini-Hill A, et al: Total and free estrogens and androgens in postmenopausal women with hip fractures. J Clin Endocrinol 1982;54:115-120
22. Barlow DH, Abdalla HI, Roberts ADG, et al: Long-term hormone implant therapy: Hormonal and clinical effects. Obstet Gynecol 1986;67:321-325
23. Nawata H, Tanaka S, Tanaka S, et al: Aromatase in bone cell: Association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol 1995;53:165-174
24. Davis SR, McCloud P, Strauss BJG, et al: Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-236
25. Watts NB, Notelovitz M, Timmons MC, et al: Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopausal women. Obstet Gynecol 1995; 85:529-537
26. Chesnut CH III, Nelp WB, Baylink DJ, et al: Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass. Metabolism 1977;26:267-277
27. Cauley JA, Gutai JP, Kuller LH, et al: Endogenous estrogen levels and calcium intakes in postmenopausal women: Relationships with cortical bone measures. JAMA 1988;260: 3150-3155
28. Marshall D, Hohnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1966;312:1254-1259
29. Geusens P, Dequeker J, Verstraeten A, et al: Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions. Maturitas 1986;8:281-289
30. Bachmann GA, Leiblum SR, Sandler B, et al: Correlates of sexual desire in post-menopausal women. Maturitas 1985;7: 211-216
31. Studd JWW, Collins WP, Chakravarti S, et al: Oestradiol and testosterone implants in the treatment of psychosexual problems in the post-menopausal woman. Br J Obstet Gynaecol 1977;84:314-315
32. Greenblatt RB: Androgenic therapy in women. J Clin Endocrinol Metab 1942;2:665-666
33. Greenblatt RB, Barfield WE, Garner JF, et al: Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. J Clin Endocrinol 1950;10:1547-1558
34. Beard MK, Curtis LR: Libido, menopause, and estrogen replacement therapy. Postgrad Med 1989;86:225-228
35. McKeon VA: Hormone replacement therapy: Evaluating the risks and benefits. J Obstet Gynecol Neonate Nurse 1993; 23:647-657
36. Burger HG, Hailes J, Menelaus M, et al: The management of persistent menopausal symptoms with oestradiol-testosterone implants: Clinical, lipid and hormonal results. Maturitas 1984;6:351-358
37. Kapetanakis E, Dmowski WP, Auletta F, et al: Endocrine and clinical effects of estradiol and testosterone pellets used in long-term replacement therapy. Int J Gynaecol Obstet 1982; 20:387-399
38. Brincat M, Magos A, Studd JWW, et al: Subcutaneous hormone implants for the control of climacteric symptoms. Lancet 1984;1:16-18
39. Cardozo L, Gibb DMF, Tuck SM, et al: The effects of subcutaneous hormone implants during the climacteric. Maturitas 1984;5:177-184
40. Sherwin BB, Gelfand MM: The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-409
41. Dow MGT, Hart DM, Forrest CA: Hormonal treatments of sexual unresponsiveness in postmenopausal women: A comparative study. Br J Obstet Gynaecol 1983;90:361-366
42. Leiblum S, Bachmann G, Kemmann E, et al: Vaginal atrophy in the postmenopausal woman: The importance of sexual activity and hormones. JAMA 1983;249:2195-2198
43. Bachmann GA, Leiblum SR, Kemmann E, et al: Sexual expression and its determinants in the post-menopausal woman. Maturitas 1984;6:19-29
44. Rebar RW: Unanswered questions in hormonal replacement therapy. Exp Gerontol 1994;29:447-461
45. Anderson E, Hamburger S, Liu JH, et al: Characteristics of menopausal women seeking assistance. Am J Obstet Gynecol 1987;156:428-433
46. Caldwell BM, Watson RI. An evaluation of psychologic effects of sex hormone administration in aged women: I. Results of therapy after six months. J Gerontol 1952;7:228-244
47. Sherwin BB, Gelfand MM: Sex steroids and affect in the surgical menopause: A double-blind, crossover study. Psychoneuroendocrinology 1985;10:325-335
48. Sherwin BB: Sex hormones and psychological functioning in postmenopausal women. Exp Gerontol 1994;29:423-430
49. Ditkoff EC, Crary WG, Cristo M, et al: Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-995
50. Sherwin BB: Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affect Disord 1988;14:177-197
51. Weinstein L: Hormonal therapy in the patient with surgical menopause. Obstet Gynecol 1990;75:47S-50S
52. Breckwoldt M, Keck C, Karck U: Benefits and risks of hormone replacement therapy (HRT). J Steroid Biochem Mol Biol 1995;53:205-208
53. Sherwin BB, Gelfand MM: Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985;151:153-160
54. Montgomery JC, Appleby L, Brincat M, et al: Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987;1:297-299
55. Need AG, Morris HA, Hartley TF, et al: Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic menopausal women. Calcif Tissue Int 1987;41:7-10
56. Brincat M, Moniz CJ, Studd JWW, et al: Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985;92:256-259
57. Bauer DC, Grady D, Pressman A, et al: Skin thickness, estrogen use, and bone mass in older women. Menopause 1994; 1:131-136
58. Gelfand MM: Treating menopausal symptoms with estrogen and androgen preparations. Contemp OB-GYN 1994;39: 31-36
59. Timmons MC, Young R, Barrett-Connor E, et al: Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. Presented at the 6th Annual North American Menopause Society Meeting, San Francisco, September 21-23, 1995
60. Barret-Connor E, Timmons C, Young R, et al: Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. J Womens Health (in press)
61. Urman B, Pride SM, Yuen BH: Elevated serum testosterone, hirsutism, and virilism associated with combined estrogen-androgen hormone replacement therapy. Obstet Gynecol 1991;77:595-598
62. Westaby D, Ogle SJ, Paradinas FJ, et al: Liver damage from long-term methlytestosterone. Lancet 1977;2:262-263
63. Physicians' Desk Reference. Fiftieth edition. Mont Vale, New Jersey, Medical Economics, 1996
64. National Hospital Discharge Survey, 1988-1990. Special request. Bethesda, Centers for Disease Control, 1996
65. National Center for Health Statistics, 1992. Special request. Bethesda, Centers for Disease Control, 1996
66. Belchetz PE: Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-1071
67. LaRosa JC: Metabolic effects of estrogens and progestins. Fertil Steril 1994;62:140S-146S
68. Walsh JME, Grady D: Treatment of hyperlipidemia in women. JAMA 1995;274:1152-1158
69. Stevenson JC, Crook D, Godsland IF, et al: Oral versus transdermal hormone replacement therapy. Int J Fertil (suppl) 1993;38:30-35
70. Ettinger B, Friedman GD, Bush T, et al: Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6-12
71. Matthews KA, Kuller LH, Wing RR, et al: Health prior to hormone use: Reply. Am J Epidemiol 1996;143:983-984
72. Sarrel PM: How progestins compromise the cardioprotective effects of estorgens. Menopause 1995;2:187-190
73. Hickok LR, Toomey C, Speroff L: A comparison of esterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993;82:919-924
74. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867
75. Honoré EK, Williams K, Adams MR, et al: Methyltestosterone does not diminish the beneficial effects of estrogen replacement therapy on coronary artery reactivity in Cynomolgus monkies. Menopause 1996;3:20-26
76. Yue P, Chatterjee K, Beale C, et al: Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995;91: 1154-1160
77. Chou TM, Sudhir K, Amidon TM, et al: Coronary vasorelaxation induced by testosterone in vivo is gender independent (abstr). J Am Coll Cardiol 1995;25:33A
78. Sherwin BB, Gelfand MM, Schucher R, et al: Postmenopausal estrogen and androgen replacement therapy and lipoprotein lipid concentrations. Am J Obstet Gynecol 1987;156: 414-419
79. Barnes RB, Roy S, Lobo RA: Comparison of lipid and androgen levels after conjugated estrogen or depomedroxyprogesterone acetate treatment in postmenopausal women. Obstet Gynecol 1985;66:216-219
80. Youngs DD, Hoogwerf BJ, Schover LR, et al: Circulating lipid and lipoprotein concentrations with oral estrogen-androgen hormone replacement therapy. Cleve Clin J Med 1992;59:357-358
81. Persson I, Adami H-O, Bergkvist L, et al: Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J 1989;298:147-151
82. Ziel HK, Finkle WD: Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293:1167-1170
83. The Writing Group for the PEPI trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The postmenopausal estrogen-progestin interventions (PEPI) trial. JAMA 1996:275:370-376
84. Hackenberg R, Beck S, Filmer A, et al: Androgen responsiveness of the new human endometrial cancer cell line MFE-296. Int J Cancer 1994;57:117-122
85. Yamamoto T, Kitawaki J, Urabe M, et al: Estrogen productivity of endometrium and endometrial cancer tissue: Influence of aromatase on proliferation of endometrial cancer cells. J Steroid Biochem Mol Biol 1993;44:463-468
86. Nagamani M, Doherty MG, Smith ER, et al: Increased bioactive luteinizing hormone levels in postmenopausal women with endometrial cancer. Am J Obstet Gynecol 1992;167: 1825-1830
87. Steinberg KK, Thacker SB, Smith J, et at. A meta-analysis of the effect of estrogen replacement on the risk of breast cancer. JAMA 1991;265:1985-1990
88. Stanford JL, Weiss NS, Voight LF, et al: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995; 274:137-142
89. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;24:1589-1593
90. Nathanson IT, Kelley RM: Hormonal treatment of cancer. N Engl J Med 1952;246:135-145
91. Inskip PD: Pelvic radiotherapy, sex hormones, and breast cancer. Cancer Cause Control 1994;5:471-478
92. Sherwin BB, Gelfand MM: Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am J Obstet Gynecol 1984;148:552-557
93. Sherwin BB: Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-357
94. Wiklund I, Berg G, Hammar M, et al: Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas 1992;14:225-236
95. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al: Estrogen replacement therapy: I. A 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979;53:277-281